钙通道阻滞剂是否通过抑制细胞凋亡对激素治疗前列腺癌产生不利影响

T. Buchholz, Y. Tony, Douglas Martin, C. R. Powell, P. Johnstone, P. Allen
{"title":"钙通道阻滞剂是否通过抑制细胞凋亡对激素治疗前列腺癌产生不利影响","authors":"T. Buchholz, Y. Tony, Douglas Martin, C. R. Powell, P. Johnstone, P. Allen","doi":"10.1046/J.1525-1411.1999.00004.X","DOIUrl":null,"url":null,"abstract":"Background: Hormonal therapy of prostate cancer is mediated, in part, through apoptosis. This process is dependent on intracellular calcium influx. This study investigates whether the use of calcium channel blockers inhibits this process and thereby negatively impacts hormonal therapy. Methods: Records from patients dying from metastatic prostate cancer in three medical centers were reviewed. The date of diagnosis, date of metastatic disease, date of death, Gleason sum, type of hormone therapy, and calcium channel blocker used were recorded. Results: Of the 180 patients, 26 were on a calcium channel blocker at the time of their hormonal therapy. The length of survival from the time of hormone therapy to death in these patients did not differ from the 154 patients not on a calcium channel blocker (respective median survival time of 819 days versus 730 days, p = 0.913—log rank test of the survival curves). Similarly, there were no differences in length of survival from the date of diagnosis between the two groups. Other analyzed factors (type of hormone therapy, Gleason score, and interval between diagnosis and metastatic disease) also did not affect length of survival from the time of hormonal treatment or time of diagnosis. Conclusion: We found no evidence that calcium channel blockers inhibit the therapeutic efficacy of hormonal treatment for metastatic prostate cancer.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"279 1","pages":"43-48"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Do Calcium Channel Blockers Adversely Affect Hormonal Treatment of Prostate Cancer Through an Inhibition of Apoptosis\",\"authors\":\"T. Buchholz, Y. Tony, Douglas Martin, C. R. Powell, P. Johnstone, P. Allen\",\"doi\":\"10.1046/J.1525-1411.1999.00004.X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Hormonal therapy of prostate cancer is mediated, in part, through apoptosis. This process is dependent on intracellular calcium influx. This study investigates whether the use of calcium channel blockers inhibits this process and thereby negatively impacts hormonal therapy. Methods: Records from patients dying from metastatic prostate cancer in three medical centers were reviewed. The date of diagnosis, date of metastatic disease, date of death, Gleason sum, type of hormone therapy, and calcium channel blocker used were recorded. Results: Of the 180 patients, 26 were on a calcium channel blocker at the time of their hormonal therapy. The length of survival from the time of hormone therapy to death in these patients did not differ from the 154 patients not on a calcium channel blocker (respective median survival time of 819 days versus 730 days, p = 0.913—log rank test of the survival curves). Similarly, there were no differences in length of survival from the date of diagnosis between the two groups. Other analyzed factors (type of hormone therapy, Gleason score, and interval between diagnosis and metastatic disease) also did not affect length of survival from the time of hormonal treatment or time of diagnosis. Conclusion: We found no evidence that calcium channel blockers inhibit the therapeutic efficacy of hormonal treatment for metastatic prostate cancer.\",\"PeriodicalId\":22947,\"journal\":{\"name\":\"The open prostate cancer journal\",\"volume\":\"279 1\",\"pages\":\"43-48\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The open prostate cancer journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1046/J.1525-1411.1999.00004.X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open prostate cancer journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/J.1525-1411.1999.00004.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:前列腺癌的激素治疗部分是通过细胞凋亡介导的。这一过程依赖于细胞内钙的流入。本研究探讨钙通道阻滞剂的使用是否会抑制这一过程,从而对激素治疗产生负面影响。方法:回顾三家医疗中心转移性前列腺癌死亡患者的记录。记录诊断日期、转移性疾病日期、死亡日期、格里森总和、激素治疗类型和使用的钙通道阻滞剂。结果:在180例患者中,26例在激素治疗时使用钙通道阻滞剂。这些患者从激素治疗到死亡的生存时间与154名未使用钙通道阻滞剂的患者没有差异(各自的中位生存时间分别为819天对730天,p = 0.913-log生存曲线秩检验)。同样,自诊断之日起,两组之间的生存时间也没有差异。其他分析的因素(激素治疗类型、Gleason评分、诊断与转移性疾病之间的间隔)也不影响从激素治疗时间或诊断时间算起的生存时间。结论:没有证据表明钙通道阻滞剂会抑制激素治疗转移性前列腺癌的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Do Calcium Channel Blockers Adversely Affect Hormonal Treatment of Prostate Cancer Through an Inhibition of Apoptosis
Background: Hormonal therapy of prostate cancer is mediated, in part, through apoptosis. This process is dependent on intracellular calcium influx. This study investigates whether the use of calcium channel blockers inhibits this process and thereby negatively impacts hormonal therapy. Methods: Records from patients dying from metastatic prostate cancer in three medical centers were reviewed. The date of diagnosis, date of metastatic disease, date of death, Gleason sum, type of hormone therapy, and calcium channel blocker used were recorded. Results: Of the 180 patients, 26 were on a calcium channel blocker at the time of their hormonal therapy. The length of survival from the time of hormone therapy to death in these patients did not differ from the 154 patients not on a calcium channel blocker (respective median survival time of 819 days versus 730 days, p = 0.913—log rank test of the survival curves). Similarly, there were no differences in length of survival from the date of diagnosis between the two groups. Other analyzed factors (type of hormone therapy, Gleason score, and interval between diagnosis and metastatic disease) also did not affect length of survival from the time of hormonal treatment or time of diagnosis. Conclusion: We found no evidence that calcium channel blockers inhibit the therapeutic efficacy of hormonal treatment for metastatic prostate cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信